SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
137Results of WIN-R study reported: investorshub.comDewDiligence_on_SI-5/25/2006
136<i>Anyone got a take on these?</i> investorshub.com Hopefully, IDIDewDiligence_on_SI-5/24/2006
135Idenix' (IDIX) hepatitis abstracts at DDW: investorshub.com Anyone got a ttuck-5/24/2006
134Hepatitis C Profile In U.S. Suggests Consequences Of The Disease Are Yet To ComeLJM-5/18/2006
133didn't feel like starting a new thread, "indications -- digestive diseascaram(o)uche-4/12/2006
132Medivir: Medivir's Antiviral MIV-210 (FLG) Inhibits Hepatitis B Virus (HBV) nigel bates-3/28/2006
131HCV - VRX Viramidine misses non-inferiority Valeant Pharmaceuticals Reports VISIRWIN JAMES FRANKEL-3/21/2006
130Viral Hepatitis conference next week..I didn't know where to park this.. srzeta1961-2/24/2006
129Drug-Related Hepatotoxicity NEJM, February 16, 2005 Victor J. Navarro, M.D., azeta1961-2/15/2006
128Drug-Related Hepatotoxicity NEJM, February 16, 2005 Victor J. Navarro, M.D., azeta1961-2/15/2006
127Thanks. eomfred hayes-2/15/2006
126You should keep an eye on ANDS.kenhott-2/15/2006
125This caught my eye. Don't know anything about ANDS but looks like a good resfred hayes-2/14/2006
124Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps scaram(o)uche-2/7/2006
123MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment Naive PatientsJohn McCarthy-1/23/2006
122Press Release Source: Peregrine Pharmaceuticals, Inc. Peregrine Announces AcceJohn McCarthy-1/18/2006
121>>SAN FRANCISCO, Jan. 9 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, tuck-1/9/2006
120>>Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-tuck-1/9/2006
119In the context of recent news about Idenix' and Vertex's HCV drugs intertuck-1/9/2006
118Novel Interferon Signaling Pathways Explored in Special Issue of Journal of InteJohn McCarthy-12/28/2005
117Anadys Pharmaceuticals to Initiate 28-Day Clinical Trial of ANA975 in Patients WJohn McCarthy-12/22/2005
116REHOVOT, Israel, December 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals John McCarthy-12/16/2005
115Dynavax to Present Data on Phase 2/3 Clinical Trial of HEPLISAV(TM) Hepatitis B John McCarthy-12/7/2005
114Par, Three Rivers Get FDA OK on Ribasphere Monday December 5, 4:00 pm ET Par PJohn McCarthy-12/6/2005
113Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for InveJohn McCarthy-12/5/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News